Weekly low-dose liraglutide reduced a dialysis patient's uncontrollable thirst from 10/10 to 3/10 and halved her dangerous fluid overload — a novel use of a GLP-1 peptide as a brain-targeted thirst modulator.
Thirst: 10→3/10weekly low-dose liraglutide dramatically reduced intractable polydipsia in a non-diabetic dialysis patient, halving dangerous interdialytic fluid gain
What the researchers found
Weekly low-dose liraglutide (1.2 mg/week) reduced interdialytic weight gain from 5.72% to 2.72% and decreased thirst from 10/10 to 3/10 on an analog scale in a non-diabetic hemodialysis patient with refractory polydipsia. The treatment stabilized blood pressure and improved dialysis tolerance in a patient whose management was severely limited by baseline hypotension and hemodynamic instability. The mechanism is proposed to be GLP-1 receptor-mediated modulation of neural circuits controlling thirst, independent of glycemic effects.
Why it matters
Fluid overload from uncontrollable thirst is a dangerous and common problem in dialysis patients with no good treatments. This case demonstrates an entirely novel use of a GLP-1 peptide drug — not for diabetes or weight loss, but as a thirst suppressant targeting brain circuits that regulate drinking behavior. It reframes non-compliance with fluid restrictions as a treatable neuroendocrine condition rather than a behavioral failure.
The numbers in context
Liraglutide 1.2 mg weekly · IDWG reduced 5.72%→2.72% · thirst 10/10→3/10 · previous peak IDWG 8% (6L) · non-diabetic patient · stabilized BP from 90/60 mmHg baseline
How the study worked
Single case report of a 66-year-old woman with ESRD on chronic hemodiafiltration without residual kidney function. After refractory hypervolemia from intractable polydipsia, liraglutide 1.2 mg was initiated once weekly (intentionally below standard dosing). Interdialytic weight gain, thirst (visual analog scale), blood pressure, and dialysis tolerance were monitored.
Who was studied
Single 66-year-old non-diabetic woman with ESRD on chronic hemodialysis with refractory polydipsia
What this study cannot tell us
Single case report — cannot generalize to other patients. No control or comparison treatment. Weekly liraglutide dosing is off-label and non-standard (daily 1.2-1.8 mg is approved). The mechanism of thirst suppression is proposed but not directly demonstrated. Long-term safety of GLP-1 agonists in anuric ESRD patients not established. Published in Cureus, a lower-impact journal.
How to read the evidence
This is a single case report — the lowest level of clinical evidence. While the results are dramatic and the proposed mechanism is scientifically plausible, this cannot be generalized without controlled trials. The off-label, non-standard dosing adds uncertainty.
When this study was published
Published in 2026, this is the first reported use of a GLP-1 peptide drug specifically to treat intractable thirst in a dialysis patient, representing a novel therapeutic frontier.
The bigger picture
GLP-1 receptor agonists continue to reveal unexpected therapeutic applications. This case adds thirst regulation to the growing list of GLP-1 brain effects (which already includes appetite, nausea, and neuroprotection). For the estimated 3.4 million hemodialysis patients worldwide, uncontrolled thirst and fluid overload are major causes of morbidity and mortality. If confirmed in clinical trials, GLP-1 peptide-based thirst modulation could transform nephrology practice.
Questions still open
- Would this thirst-suppressing effect of liraglutide replicate in a larger cohort of dialysis patients with polydipsia?
- Are newer GLP-1 drugs like semaglutide (which have stronger brain penetration) even more effective for thirst modulation?
- What are the long-term safety implications of GLP-1 agonist use in patients with no kidney function?
Common questions
Why is uncontrollable thirst dangerous for dialysis patients?
How can a diabetes drug suppress thirst?
Read the original research
Weekly Liraglutide for the Management of Intractable Polydipsia and Interdialytic Weight Gain in a Patient on Hemodialysis: A Case Report.
Cureus, 18(1), e102197
Citation
Mora-Bravo, Franklin; Morales, Pamela T; Pincay, Gabriela; Pineda, Samantha; Morales, Brayan. (2026). Weekly Liraglutide for the Management of Intractable Polydipsia and Interdialytic Weight Gain in a Patient on Hemodialysis: A Case Report.. Cureus, 18(1), e102197. https://doi.org/10.7759/cureus.102197